2022 American Transplant Congress
Preemptive Therapy in Cytomegalovirus (CMV) Seropositive Donor to Seronegative Recipient Liver Transplants
Transplant, Atrium Health's Carolinas Medical Center, Charlotte, NC
*Purpose: To evaluate if a preemptive therapy strategy can prevent CMV disease and induce CMV seroconversion.*Methods: Observational data collection for CMV D+/R- adult liver transplant…2022 American Transplant Congress
Risk for Loss of Hepatitis B Surface Antibody or Hepatitis B Reactivation in Kidney Transplant Recipients Receiving Lymphocyte Depleting Induction
*Purpose: Although used in over 60% of kidney transplant recipients, the impact of lymphocyte depleting induction on hepatitis B surface antibody (HBsAb) and hepatitis B…2022 American Transplant Congress
Letermovir for Prophylaxis of Cytomegalovirus After Solid Organ Transplantation: A Single-Center, Observational Study
*Purpose: Cytomegalovirus (CMV) infections cause significant complications post-transplant; however, prophylactic medications are often limited by toxicities. Letermovir is a novel terminase inhibitor specific to CMV…2022 American Transplant Congress
Recurrent Cytomegalovirus and the Role of Secondary Prophylaxis in Heart and Lung Transplant Recipients
*Purpose: This study aimed to describe the incidence of cytomegalovirus (CMV) recurrence in heart and lung transplant recipients and the effect of secondary prophylaxis (SP)…2022 American Transplant Congress
Effect of Micafungin Bridging on Prevention of Invasive Candidiasis Post Lung Transplantation
*Purpose: This study aims to determine the effect of micafungin, added as a bridging agent to azole antifungal prophylaxis, in lung transplantation patients with positive…2022 American Transplant Congress
An Interventional Study Using Cell-Mediated Immunity to Guide Primary Prophylaxis for CMV Infection in Organ Transplant Recipients: A Multi-Center Study
*Purpose: There are limited interventional studies using CMV cell-mediated immunity to guide the duration of antiviral prophylaxis. We aimed to use CMV CMI to guide…2022 American Transplant Congress
Cmv-Specific Cell-Mediated Immune Reconstitution in High-Risk Hematopoietic Cell Transplant Recipients Receiving Letermovir Prophylaxis
*Purpose: In the absence of antiviral prophylaxis following Hematopoietic Cell Transplant (HCT), the incidence of clinically significant cytomegalovirus reactivation (cCMV) is 30% in CMV seropositive…2022 American Transplant Congress
Evaluation of Prophylactic Valganciclovir Dosing in Kidney Transplant Recipients at an Urban Transplant Institution
*Purpose: Dosing and duration of cytomegalovirus (CMV) prophylaxis with valganciclovir (VGC) in kidney transplant (KT) recipients is variable by transplant center. Prior studies have shown…2022 American Transplant Congress
Incidence of Urinary Tract Infection or Asymptomatic Bacteriuria in Kidney Transplant Recipients with Sulfamethoxazole-Trimethoprim vs. Pentamidine for Pneumocystis Jiroveci Pneumonia Prophylaxis
University Health, San Antonio, TX
*Purpose: To compare the incidence of urinary tract infection (UTI) or asymptomatic bacteriuria (ASB) post-kidney transplant (KT) with multiple Pneumocystis jiroveci pneumonia (PJP) prophylaxis regimens*Methods:…2022 American Transplant Congress
Does a Second Transplant Increase the Risk for CMV Infection? An Evaluation of the Incidence of CMV Viremia in the Previously Transplanted Kidney Recipient
*Purpose: Cytomegalovirus (CMV) viremia is a common complication of kidney transplant recipients (KTR) with significant morbidity/mortality. Patients who receive multiple transplants are potentially at a…
- 1
- 2
- 3
- …
- 14
- Next Page »